The US Food and Drug Administration (FDA) has registered an additional indication for the use of brexpiprazole. The drug will be available for the treatment of agitation/anxiety associated with dementia in Alzheimer's disease. This is the first formulation approved by the FDA for this indication.
Alzheimer's disease is the most common cause of dementia. Patients with dementia often exhibit behavioral and psychological disorders. Agitation (anxiety) is one of the most persistent, complicated, stressful and costly aspects of caring for patients with behavioral and psychological symptoms of dementia.
- Agitation/anxiety is one of the most common and difficult problems in caring for patients with Alzheimer's dementia. Agitation can include symptoms rangi...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
